---
title: "UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for severe asthma and CRSWNP"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295535838.md"
description: "Verekitug, a potent TSLP receptor antagonist, showed strong efficacy and safety in Phase 2 trials for severe asthma and CRSWNP, supporting quarterly dosing and broad patient eligibility. Phase 3 trials are planned for 2027, targeting a $35B+ global market opportunity.Original document: Upstream Bio, Inc. [UPB] Slides Release — Aug. 11 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-11T12:16:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295535838.md)
  - [en](https://longbridge.com/en/news/295535838.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295535838.md)
generator: "portal-rs"
---

# UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for severe asthma and CRSWNP

Verekitug, a potent TSLP receptor antagonist, showed strong efficacy and safety in Phase 2 trials for severe asthma and CRSWNP, supporting quarterly dosing and broad patient eligibility. Phase 3 trials are planned for 2027, targeting a $35B+ global market opportunity.

Original document: Upstream Bio, Inc. \[UPB\] Slides Release — Aug. 11 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [UPB.US](https://longbridge.com/en/quote/UPB.US.md)

## Related News & Research

- [Upstream Bio plans Q1 2027 start for Phase 3 verekitug trials in severe asthma, nasal polyps](https://longbridge.com/en/news/297641472.md)
- [Upstream Bio, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.73) — 10-Q Summary](https://longbridge.com/en/news/295528768.md)
- [Upstream Bio posts corporate presentation highlighting verekitug Phase 3 plans in severe asthma, CRSwNP](https://longbridge.com/en/news/295528626.md)
- [Tyra Biosciences to present initial Phase 2 SURF302 data for oral dabogratinib in intermediate-risk bladder cancer on Sept. 9](https://longbridge.com/en/news/298034950.md)
- [AbbVie Completes Acquisition of Apogee Therapeutics | ABBV Stock News](https://longbridge.com/en/news/297915640.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**